SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer
3 references·0 citing·12 second hop
A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer (2015)A Markov model to evaluate cost-effective…MARKOV MODELING AND DISCRETE EVENT SIMULATION IN HEALTH CARE: A SYSTEMATIC COMPARISON (2014)MARKOV MODELING AND DISCRETE …A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer (2011)A cost-benefit analysis of be…Health state utilities for metastatic breast cancer (2006)Health state utilities for me…Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation (2009)Delivering affordable cancer care in high-income countries (2011)Cost-Effectiveness in Health and Medicine (1996)Quality of life and pharmacoeconomics in clinical trials (1996)EQ-SD: a measure of health status from the EuroQol Group (2001)Health-state utility values in breast cancer (2010)Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report (2016)Health state utilities in non–small cell lung cancer: An international study (2016)Markov Models in Medical Decision Making (1993)Methods for the Economic Evaluation of Health Care Programmes (2005)A taxonomy of model structures for economic evaluation of health technologies (2006)The Diffusion of Discrete Event Simulation Approaches in Health Care Management in the Past Four Decades: A Comprehensive Review (2020)
this work references cited by second hop

References

  • 2006Health state utilities for metastatic breast cancer356 cited
  • 2014MARKOV MODELING AND DISCRETE EVENT SIMULATION IN HEALTH CARE: A SYSTEMATIC COMPARISON89 cited
  • 2011A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer68 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work